CDK4 6 Inhibitor Safety and Adherence

CE / CME

Strategies for Managing AEs and Promoting Adherence to CDK4/6 Inhibitors

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: February 11, 2025

Expiration: August 10, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1: Pneumonitis With Abemaciclib



  • 32-yr-old Asian female was diagnosed with T2N1 disease (2 positive nodes), ER+/HER2-, grade 3

  • She underwent surgery, chemotherapy (ddAC-T) and radiation;  premenopausal after chemo, BRCA negative 

  • Treated with adjuvant abemaciclib 150 mg BID, ovarian suppression and anastrozole; she developed a cough after being on treatment for 6 mo; CT chest showed opacities consistent with ILD

In addition to holding abemaciclib and initiating treatment with a steroid taper, which of the following would you recommend as the best management for this patient’s grade 2 pneumonitis?

2.

Which of the following side effects do you currently monitor closely in your patients being treated with ribociclib?